Individuals with type 1 diabetes, thyroid cancer, multiple endocrine neoplasia, or end stage kidney disease at any time until cohort entry or individuals with dialysis or the latest eGFR 70 years, by males versus females, by insulin use, by atherosclerotic cardiovascular disease (i.e., myocardial infraction, angina, coronary artery disease, coronary revascularization, peripheral artery disease, aortic atherosclerotic disease, or cerebrovascular disease), by renal insufficiency (i.e., chronic kidney disease or the latest eGFR 70 years (HR [95% CI]: 0.95 [0.831.08])
Semaglutide GLP-1 can help patients achieve weight loss by reducing appetite, creating a feeling of fullness, and improving insulin sensitivity
The same analysis also found that individuals with monthly cost-sharing less than $60 were significantly more likely to continue treatment than those paying more than $60 per month
In a direct head-to-head comparison, tirzepatide demonstrated similar benefits in reducing MACE as semaglutide
It led to significant weight loss as well